Salesforce's AI Business Is Growing More Than 200%, but the Stock Is Near a 52-Week Low. Something Has to Give.

Salesforce said Agentforce annual recurring revenue reached $1.2 billion in fiscal Q1 2027, up 205% year over year and up 50% from $800 million at fiscal 2026 year-end. However, core revenue growth slowed to 13% year over year, or about 9% excluding Informatica, while the stock is down about 37% in 2026 and trades near a 52-week low. Management still expects organic revenue growth to reaccelerate in the second half of fiscal 2027, and the company has executed a $25 billion share repurchase.

Analysis

The market is treating CRM like a classic subscription-disruption story, but the important second-order effect is that AI adoption may actually be increasing the value of a trusted enterprise workflow layer rather than replacing it. If large customers are adding seats while layering agents on top, the economic model shifts from pure user-count exposure to a hybrid of seats + automation consumption, which can stabilize growth even if traditional SaaS spending slows. That makes the current drawdown more about positioning and narrative fatigue than a clean fundamentals break.

The bigger near-term variable is not AI monetization speed; it's whether management can prove organic growth inflects in the back half of fiscal 2027 without needing acquisition support. The market will likely tolerate soft patches in marketing/commerce and Tableau only if core sales cloud and Agentforce show enough traction to offset them, because otherwise the growth mix keeps deteriorating while valuation remains hostage to sentiment. Oracle’s AI spending shock also matters indirectly: it reinforces that investors are now discounting capital intensity and free-cash-flow volatility across software, which raises the bar for any company selling an AI transformation story.

The contrarian read is that CRM may be one of the few large-cap software names where AI is early enough to be underestimated rather than fully priced. At roughly 19x earnings, downside looks partly de-risked unless organic growth reaccelerates materially worse than management expects; the real risk is a prolonged dead zone where the stock stays cheap but unowned. If Agentforce continues compounding and seat expansion persists, the bear case starts to look more like a delayed monetization story than a thesis about structural displacement.

Key Decisions for Investors

• Long CRM common into the next earnings cycle with a 3-6 month horizon; use the current drawdown as entry, targeting a re-rating toward prior mid-cycle multiples if organic growth reaccelerates. Risk: if core revenue remains sub-10% and management misses H2 FY27 guidance, the stock can stay range-bound despite AI strength.
• Buy CRM call spreads expiring after the next two earnings reports; structure for a modest upside move rather than a full trend reversal. This captures the asymmetry from a low multiple and de-risks the thesis if the stock remains volatile while the market waits for proof.
• Short ORCL against a long CRM basket exposure over the next 1-2 quarters as a relative-value hedge on AI capex skepticism. ORCL is more exposed to free-cash-flow scrutiny, while CRM has a better chance of being rewarded for evidence of AI-driven workflow expansion.
• Avoid chasing INFA here; treat it as an integration risk rather than a standalone AI beneficiary. Any incremental upside from CRM ownership is more likely to accrue to the platform parent than to the acquired asset in the near term.
• If CRM breaks materially below recent lows after the next guidance update, cut long exposure quickly; the stock is pricing in a delayed but real inflection, so a second miss would convert this from cheap to a value trap.